Primary care providers can effectively treat patients with hepatitis C

Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment success and provider satisfaction, according to a presentation at the 2016 AASLD Liver Meeting this month in Boston. The advent of direct-acting antivirals used in interferon-free regimens has made treatment for chronic hepatitis C much more effective. In add

The Week in Review: Nov 11 – Nov 18, 2016

Friday, November 18, 2016 AASLD, 2016: Focus on Liver Cancer and DAAs This year at The Liver Meeting® — held by the American Association for the Study of Liver Diseases (AASLD 2016) — there were a lot of presentations on Liver Cancer (HCC) and the new DAAs.  Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States. The proportion of hepatitis C patients with cirrhosi...

AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis - 100 percent of patients achieved SVR12 in a modified intent-to-treat analysis - G/P is an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose com...

US: Large Study Identifies Increase of Cirrhosis in Hepatitis C Patients

BOSTON, Nov. 11, 2016 /PRNewswire/ -- Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States, according to research presented at The Liver Meeting® — held by the American Association for the Study of Liver Diseases. Hepatitis C has been linked to cirrhosis (i.e., scarring of the liver), decompensated cirrhosis, and death, but the extent of the prevalence of thes...

The impact of sustained virological response to HCV infection on long term risk of hepatocellular carcinoma: the BC Hepatitis Testers Cohort

A study of the entire population of people treated for hepatitis C in British Columbia province between 1990 and 2013, Canada found that the risk of liver cancer was reduced by 80% in people cured of hepatitis C compared to those who were not cured. This study did not look at the relationship between exposure to DAAs and liver cancer risk. The study identified 8147 people treated with interferon-based regimens, 57% of whom were cured. Treated individuals

Is There an Increased Risk of Cancer After Taking Direct-Acting Antiviral Medication?

BOSTON, Nov. 11, 2016 /PRNewswire/ -- A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication. However, they might be at an increased for more aggressive, infiltrative patterns of cancer, should they develop it. "Dat...

Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three Phase 2 clinical trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1), the company’s investigational all-oral,

AASLD 2016: Efficacy of Antiviral Agents for Hepatitis C in HCC Patients

George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC). The study aimed to understand the real-world effectiveness of antiviral agents sofosbuvir (SOF), ledipasvir/sofosbuvir (LDV/ SOF) and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) by h

AASLD 2016: Cost-Benefit of Treating Hepatitis C in HCC Patients Before Transplant

Dr. Gonzalez and his team developed a model to determine if it was cost-effective to treat U.S. hepatitis C with all oral direct acting antivirals for HCC patients on the waiting list for liver transplant. The goal was to determine if was more cost-effective to treat pre-transplant or post-transplant. Data related to transition to progression of HCC and progression of disease and the efficacy of antiviral therapy were used for the analysis. The study foun

USA: 3 Years – The Time It Could Take To Cure Nearly Every Veteran With Hepatitis C

BOSTON, Nov. 11, 2016 /PRNewswire/ -- Research presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — suggests the United States Veteran Healthcare Administration could potentially cure almost all U.S. veterans in its care who have hepatitis C (HCV) within two-to-three years. The availability of direct-acting antiviral agents (DAAs) in the treatment of viral hepatitis, coupled with increased ...